NEW YORK

纽约

,

，

March 24, 2026

2026年3月24日

/PRNewswire/ -- Gilgamesh Pharma, a clinical-stage neuroscience company developing breakthrough therapies for psychiatric and neurological disorders, today announced the successful closing of a $60 million Series A financing. The strong investor demand reflects the high quality of the company's clinical and preclinical pipeline..

/PRNewswire/ -- 吉尔伽美什制药公司（Gilgamesh Pharma），一家致力于开发精神疾病和神经系统疾病突破性疗法的临床阶段神经科学公司，今日宣布成功完成了6000万美元的A轮融资。强烈的投资者需求反映了该公司临床和临床前研发管线的高质量。

This is the first formal capital raise for Gilgamesh Pharma, the spinout formed following the acquisition of Gilgamesh Pharmaceuticals and bretisilocin by AbbVie in 2025 (the 'Acquisition'). The new company is led by the same management team and inherits all programs not acquired by AbbVie, as well as capital from the Acquisition and previous neuroplastogen collaboration and option-to-license deal with AbbVie initiated in 2024 (the 'Collaboration')..

这是吉尔伽美什制药公司（Gilgamesh Pharma）的首次正式融资，该公司是在艾伯维于2025年收购吉尔伽美什制药和布雷蒂西洛辛后成立的分拆公司（“收购”）。这家新公司由相同的管理团队领导，继承了所有未被艾伯维收购的项目，以及来自收购和2024年与艾伯维启动的先前神经可塑原合作及选择授权协议（“合作”）的资金。

Proceeds from this additional financing will support the advancement of Gilgamesh Pharma's portfolio of novel neuropsychiatric therapeutics, all of which are novel chemical entities (NCEs) with composition of matter IP, as well as the continued expansion of the company's discovery platform.

这笔额外融资的收益将支持吉尔伽美什制药公司新型神经精神治疗药物组合的进展，所有这些药物均为具有物质组成知识产权的新型化学实体 (NCE)，同时也将支持公司发现平台的持续扩展。

Gilgamesh Pharma recently reported positive Phase 2 results for blixeprodil (GM-1020), its non-competitive NMDA receptor antagonist being developed for the treatment of major depressive disorder (MDD). The study demonstrated clinically meaningful and statistically significant improvements in MDD, and the program is advancing into late-stage clinical studies this year..

吉尔伽美什制药公司最近报告了其非竞争性NMDA受体拮抗剂布利克塞普罗地尔（GM-1020）治疗重度抑郁症（MDD）的二期临床试验积极结果。研究表明，该药物在MDD方面表现出具有临床意义且统计学上显著的改善，该项目预计在今年进入晚期临床研究阶段。

The company's cardio-safe ibogaine analog, GM-3009, is expected to enter Phase 1 studies later this year. Gilgamesh Pharma also continues to advance its Collaboration with AbbVie to develop neuroplastogen therapeutics for neuropsychiatric disorders, providing further confidence in the potential of the company's discovery platform.

该公司的心脏安全的伊博格碱类似物GM-3009预计将在今年晚些时候进入第一阶段研究。Gilgamesh Pharma还继续推进与AbbVie的合作，开发用于神经精神疾病的神经塑化治疗药物，进一步增强了对公司发现平台潜力的信心。

Additional programs from Gilgamesh Pharma's internal pipeline are progressing toward IND-enabling studies and early clinical development..

吉尔伽美什制药公司内部管线的其他项目正在向支持新药临床试验（IND）的研究和早期临床开发推进。

The Series A financing was led by Satori Neuro, alongside participation from new and existing institutional investors, including Prime Movers Lab, which led prior Gilgamesh Pharmaceutical rounds.

A轮融资由Satori Neuro领投，新投资者和现有机构投资者共同参与，包括曾领投Gilgamesh Pharmaceutical此前几轮融资的Prime Movers Lab。

'This additional financing strengthens our ability to advance multiple programs across our pipeline while continuing to expand our discovery efforts in neuropsychiatric disease,' said Jonathan Sporn, M.D., Founder and Chief Executive Officer of Gilgamesh Pharma. 'We are encouraged by the recent Phase 2 results for GM-1020 and the continued advancement of our broader pipeline, and look forward to building on this momentum.'.

“这笔额外的融资增强了我们推进产品线中多个项目的能力，同时继续扩展我们在神经精神疾病领域的发现工作，”Gilgamesh Pharma创始人兼首席执行官Jonathan Sporn医学博士表示。“我们对GM-1020近期的二期临床结果感到鼓舞，并且我们的更广泛产品线也在持续推进，我们期待在此基础上继续发展。”

'Gilgamesh Pharma represents precisely what we look for at Satori Neuro - breakthrough science, a disciplined team, and a pipeline with the potential to fundamentally reshape how we treat the most challenging mental health conditions,' said Amy Kruse, General Partner and Chief Investment Officer, Satori Neuro.

“吉尔伽美什制药正是我们在Satori Neuro所寻找的目标——突破性的科学、纪律严明的团队，以及有可能彻底改变我们治疗最具挑战性心理健康问题的管线，”Satori Neuro普通合伙人兼首席投资官艾米·克鲁斯表示。

'Having supported this company's journey from an earlier stage, leading this oversubscribed round is both a privilege and a natural continuation of that commitment. We look forward to helping the team advance blixeprodil and their broader portfolio to the patients who need these medicines most.'.

“在支持这家公司从更早的阶段开始的发展历程后，领投这一超额认购轮次既是一种荣幸，也是我们对该承诺的自然延续。我们期待帮助团队推进布立西泮及其更广泛的产品组合，以惠及最需要这些药物的患者。”

About Gilgamesh Pharma:

关于吉尔伽美什制药：

Gilgamesh Pharma is a clinical-stage neuroscience company developing innovative new chemical entities to transform psychiatric care. The company's lead program, blixeprodil, is an oral NMDA receptor antagonist currently being developed for MDD. Blixeprodil is designed to combine rapid onset of action and robust efficacy with the convenience of oral dosing and favorable tolerability profile and is expected to enter late-stage development in 2026.

Gilgamesh Pharma是一家临床阶段的神经科学公司，致力于开发创新的新型化学实体以革新精神疾病治疗。该公司的主要项目blixeprodil是一种口服NMDA受体拮抗剂，目前正在开发用于重度抑郁症（MDD）。Blixeprodil旨在结合快速起效和显著疗效，并具备口服给药的便利性及良好的耐受性，预计将于2026年进入后期开发阶段。

Like all Gilgamesh Pharma programs, blixeprodil is an NCE supported by issued composition of matter IP. Gilgamesh Pharma's broader pipeline is focused on creating treatments that move beyond symptom management toward therapies that offer meaningful and lasting improvements in patient outcomes. Learn more about the company's therapeutic pipeline at .

像所有吉尔伽美什制药公司的项目一样，布利克塞普罗地尔是一种受物质组成专利保护的新化学实体（NCE）。吉尔伽美什制药更广泛的研发管线专注于创造超越症状管理的治疗方法，提供对患者预后有意义且持久的改善。欲了解有关公司治疗管线的更多信息，请访问。

https://www.gilgameshpharmaceutical.com/

https://www.gilgameshpharmaceutical.com/

. Follow Gilgamesh Pharma on

关注吉尔伽美什制药公司

LinkedIn

领英

and

和

X

X

.

。

Media Contact

媒体联系人

:

：

[email protected]

电子邮件地址

Investor Contact:

投资者联系人：

[email protected]

电子邮件地址

SOURCE Gilgamesh Pharma

来源：吉尔伽美什制药

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示